Antibodies targeting IL-17A have been approved for the treatment of plaque psoriasis; the observation in our cohort supports the rationale for combining anti-PD1 antibodies with IL-17A-targeted therapy in multiple cancer patients for overcoming immune suppression [44, 45]. The gene discussed is IL17A; the disease is psoriasis vulgaris.